Surveys show patients, sponsors and CROs in China
see the benefits of virtual and hybrid trials. Concerns
remain around regulatory gaps, digital data collection
and study logistics.
View White Paper
By MAGGIE MA, Director of Clinical Operations – IQVIA, China
